Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3228438 | 0.91 | MVD (0.35) | MVDBTN3A1 | |
| Bromohydrin Pyrophosphate SCHEMBL2037203 | 0.91 | MVD (0.48) | MVDBTN3A1 | |
| Bromohydrin Pyrophosphate SCHEMBL2968174 | 0.91 | MVD (0.48) | MVDBTN3A1 | |
| Bromohydrin Pyrophosphate SCHEMBL4309089 | 0.91 | MVD (0.48) | MVDBTN3A1 | |
| SCHEMBL3215427 | 0.89 | MVD (0.38) | MVDBTN3A1 | |
| Bromohydrin Triphosphate SCHEMBL2034171 | 0.88 | MVD (0.46) | MVDBTN3A1 | |
| SCHEMBL3228433 | 0.87 | MVD (0.40) | MVDBTN3A1 | |
| SCHEMBL3003035 | 0.85 | MVD (0.39) | MVDBTN3A1 | |
| SCHEMBL2997551 | 0.85 | MVD (0.40) | MVDBTN3A1 | |
| SCHEMBL13101843 | 0.83 | MVD (0.37) | MVDBTN3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1426052-B1 | Compositions comprising interleukin-2 and gamma-delta T cell activator and uses thereof | INNATE PHARMA (FR) | 2009-09-02 | — | — | EP | claimed |
| WO-2006067635-A2 | USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT | INNATE PHARMA S.A. (FR) | 2006-06-29 | — | — | WO | claimed |
| US-20050196385-A1 | Methods for producing gamma delta t cells | INNATE PHARAMA (FR) | 2005-09-08 | — | — | US | claimed |
| EP-1476540-A1 | METHODS FOR PRODUCING GAMA DELTA T CELLS | Innate Pharma (FR) | 2004-11-17 | — | — | EP | claimed |
| EP-1426052-A1 | Compositions comprising interleukin-2 and gamma-delta T cell activator and uses thereof | Innate Pharma (FR) | 2004-06-09 | — | — | EP | claimed |
| WO-2003070921-A1 | METHODS FOR PRODUCING Ϝδ T CELLS | INNATE PHARMA (FR) | 2003-08-28 | — | — | WO | claimed |
| US-20100254940-A1 | Compositions and Methods for Regulating an Immune Response in a Subject | INNATE PHARMA, S.A. (FR) | 2010-10-07 | — | — | US | disclosed |
| US-20100189681-A1 | Methods of Using Phosphoantigens Together with Interleukin-2 for the Treatment of Cancer | INNATE PHARMA S.A. (FR) | 2010-07-29 | — | — | US | disclosed |
| WO-2010049438-A2 | IMPROVED METHODS OF USING PHOSPHOANTIGENS FOR THE TREATMENT OF DISEASES | INNATE PHARMA (FR) | 2010-05-06 | — | — | WO | disclosed |
| EP-1569656-B1 | PHOSPHOANTIGENS FOR REGULATING AN IMMUNE RESPONSE | INNATE PHARMA (FR) | 2010-03-03 | — | — | EP | disclosed |
| EP-2150258-A2 | IMPROVED METHODS OF USING PHOSPHOANTIGENS TOGETHER WITH INTERLEUKIN-2 FOR THE TREATMENT OF CANCER | Innate Pharma S.A. (FR) | 2010-02-10 | — | — | EP | disclosed |
| US-20100029674-A1 | Methods of Using Phosphoantigen for the Treatment of Cancer | INNATE PHARMA, S.A. (FR) | 2010-02-04 | — | — | US | disclosed |
| US-20090304688-A1 | Methods and Compositions for Increasing the Efficiency of Therapeutic Antibodies Using Gamma Delta T Cell Activators | INNATE PHARMA S.A. (FR) | 2009-12-10 | — | — | US | disclosed |
| US-20050196385-A1 | Methods for producing gamma delta t cells | INNATE PHARAMA (FR) | 2005-09-08 | — | — | US | disclosed |
| EP-1569656-A2 | PHOSPHOANTIGENS FOR REGULATING AN IMMUNE RESPONSE | Innate Pharma (FR) | 2005-09-07 | — | — | EP | disclosed |
| WO-2005077411-A2 | COMPOSITION AND METHOD FOR THE TREATMENT OF CARCINOMA | INNATE PHARMA (FR) | 2005-08-25 | — | — | WO | disclosed |
| EP-1476540-A1 | METHODS FOR PRODUCING GAMA DELTA T CELLS | Innate Pharma (FR) | 2004-11-17 | — | — | EP | disclosed |
| WO-2004050096-A2 | PHOSPHOANTIGENS FOR REGULATING AN IMMUNE RESPONSE | INNATE PHARMA (FR) | 2004-06-17 | — | — | WO | disclosed |
| EP-1426052-A1 | Compositions comprising interleukin-2 and gamma-delta T cell activator and uses thereof | Innate Pharma (FR) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003070921-A1 | METHODS FOR PRODUCING Ϝδ T CELLS | INNATE PHARMA (FR) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100254940-A1 | Compositions and Methods for Regulating an Immune Response in a Subject | IFNG, IL2, ICOS | MVD 4043/4885BTN3A1 288/4885 |
| US-20100029674-A1 | Methods of Using Phosphoantigen for the Treatment of Cancer | CD4, CD74, TP53 | MVD 909/4885BTN3A1 536/4885 |
| US-20050196385-A1 | Methods for producing gamma delta t cells | IFNG, IL2, ICOS | MVD 2813/4885BTN3A1 500/4885 |
| US-20100189681-A1 | Methods of Using Phosphoantigens Together with Interleukin-2 for the Treatment of Cancer | IL2, IL2RA, CD4 | MVD 2950/4885BTN3A1 539/4885 |
| US-20090304688-A1 | Methods and Compositions for Increasing the Efficiency of Therapeutic Antibodies Using Gamma Delta T Cell Activators | CD4, FCGR3B, IFNG | MVD 3676/4885BTN3A1 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.